Kiora Pharmaceuticals, Inc. Common Stock (KPRX) Stock Price

KPRXStock

$2.59+0.73%52W

Market Cap$11.46M

P/E2.73x

PEG Ratio—

Div yield—

Beta-0.20

KPRX Share Price Chart

Favorite Metrics

Price vs S&P 500 (26W)20.33%

Price vs S&P 500 (4W)3.95%

VGM Score81.76

P/E Ratio (Annual)2.73x

P/CF (Annual)1.14x

Book Value / Share (Quarterly)$3.49

P/TBV (Annual)0.52x

Indicated Dividend (Annual)$0.00

Revenue Growth (3Y)81.26%

Cash Flow / Share (Quarterly)$-2.64

Price vs S&P 500 (YTD)27.64%

Net Profit Margin (TTM)70.11%

EPS (TTM)$-2.62

10-Day Avg Trading Volume0.02M

EPS Excl Extra (TTM)$-2.62

Revenue Growth (5Y)108.15%

EPS (Annual)$-2.60

ROI (Annual)-67.19%

Net Profit Margin (5Y Avg)-17004.21%

Cash / Share (Quarterly)$3.47

P/E Normalized (Annual)2.73x

ROA (Last FY)-44.67%

EBITD / Share (TTM)$-3.06

ROE (5Y Avg)-94.30%

Operating Margin (TTM)66.65%

Cash Flow / Share (Annual)$-2.68

P/B Ratio0.82x

P/B Ratio (Quarterly)0.55x

Net Income / Employee (Annual)$-833,500

Net Interest Coverage (TTM)-8.86x

ROA (TTM)-36.09%

EV / EBITDA (TTM)0.10x

EPS Incl Extra (Annual)$-2.60

Current Ratio (Annual)5.99x

Quick Ratio (Quarterly)6.19x

3-Month Avg Trading Volume0.03M

52-Week Price Return0.73%

EV / Free Cash Flow (Annual)0.50x

Revenue / Employee (TTM)$0

Tangible BV / Share (Quarterly)$2.97

P/S Ratio (Annual)0.71x

Asset Turnover (Annual)0.44x

52-Week High$2.95

Operating Margin (5Y Avg)-17089.00%

EPS Excl Extra (Annual)$-2.60

CapEx CAGR (5Y)40.83%

26-Week Price Return31.58%

Quick Ratio (Annual)5.62x

13-Week Price Return2.61%

Total Debt / Equity (Annual)0.00x

Current Ratio (Quarterly)6.68x

Enterprise Value$459,600

Revenue / Share Growth (5Y)-28.30%

Asset Turnover (TTM)0.38x

Revenue / Employee (Annual)$0

Pretax Margin (Annual)35.33%

Cash / Share (Annual)$4.54

3-Month Return Std Dev39.77%

Net Income / Employee (TTM)$-833,500

ROE (Last FY)-67.19%

Net Interest Coverage (Annual)-2.61x

EPS Basic Excl Extra (Annual)$-2.60

Total Debt / Equity (Quarterly)0.00x

EPS Incl Extra (TTM)$-2.62

ROI (TTM)-51.37%

P/S Ratio (TTM)0.71x

Pretax Margin (5Y Avg)-17045.28%

Revenue / Share (Annual)$0.00

Tangible BV / Share (Annual)$3.74

Price vs S&P 500 (52W)-17.58%

Year-to-Date Return39.59%

5-Day Price Return6.18%

EPS Normalized (Annual)$-2.60

ROA (5Y Avg)-53.44%

Net Profit Margin (Annual)22.44%

Month-to-Date Return7.42%

Cash Flow / Share (TTM)$-6.49

EBITD / Share (Annual)$-3.07

Operating Margin (Annual)27.50%

LT Debt / Equity (Annual)0.00x

ROI (5Y Avg)-94.30%

LT Debt / Equity (Quarterly)0.00x

EPS Basic Excl Extra (TTM)$-2.62

P/TBV (Quarterly)0.64x

P/B Ratio (Annual)0.45x

Pretax Margin (TTM)70.11%

Book Value / Share (Annual)$4.29

Price vs S&P 500 (13W)-0.18%

Beta-0.20x

P/FCF (Annual)1.33x

Revenue / Share (TTM)$0.00

ROE (TTM)-51.37%

52-Week Low$1.76

vGradeA

gGradeA

mGradeB

vgmGradeA

KPRX Earnings Surprise History

Q2 25-0.54est. -0.58

Q3 250.01est. -0.72

Q1 26-0.58est. -0.71

Q2 26-0.34est. -0.62

KPRX Analyst Recommendations

May 2026

Jun 2026

Jul 2026

Aug 2026

4.14

Industry Peers — Pharmaceuticals(571)

Symbol	Value Score	Growth Score	Momentum Score	Price
KPRXKiora Pharmaceuticals, Inc. Common Stock	A	A	B	$2.59
LLYEli Lilly & Co.	D	B	B	$1233.66
JNJJohnson & Johnson	D	C	B	$273.14
ABBVABBVIE INC.	D	C	B	$265.79
MRKMerck & Co., Inc.	D	C	A	$156.45
NVSNovartis AG	C	C	C	$159.98
AZNAstraZeneca PLC	C	B	C	$169.66
NVONovo-Nordisk A/S	B	C	C	$48.66
ABTAbbott Laboratories	C	C	B	$116.13
PFEPfizer Inc.	C	D	C	$28.57
VRTXVertex Pharmaceuticals Inc	D	C	B	$552.85
BMYBristol-Myers Squibb Co.	B	B	B	$67.92
SNYSanofi American Depositary Shares (Each representing one-half of one ordinary share)	B	C	C	$46.02
GSKGSK plc American Depositary Shares (Each representing two Ordinary Shares)	B	C	C	$52.07
REGNRegeneron Pharmaceuticals Inc	C	C	B	$833.56
TAKTakeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)	C	C	C	$18.35
TEVATeva Pharmaceutical Industries Limited American Depositary Shares	C	C	C	$38.10
ONCBeOne Medicines Ltd. American Depositary Shares	D	B	C	$376.37
RPRXRoyalty Pharma plc Class A Ordinary Shares	D	D	B	$62.07
ALNYAlnylam Pharmaceuticals, Inc.	D	A	D	$240.08
ZTSZOETIS INC.	B	C	D	$77.29
INSMInsmed, Inc.	F	A	C	$123.89
ROIVRoivant Sciences Ltd. Common Shares	D	F	B	$36.47
UTHRUnited Therapeutics Corp	C	C	C	$518.53
GMABGenmab A/S ADS	C	C	B	$34.36
VTRSViatris Inc. Common Stock	B	C	B	$16.72
JAZZJazz Pharmaceuticals, Inc.	B	C	B	$260.23
ASNDAscendis Pharma A/S Ordinary Share	D	A	C	$252.99
BBIOBridgeBio Pharma, Inc. Common Stock	F	A	B	$80.40
CORTCorcept Therapeutics Inc.	F	C	A	$123.57
BMRNBioMarin Pharmaceuticals Inc	C	C	C	$66.12
ARWRArrowhead Research Corporation	D	A	B	$88.88
ELANElanco Animal Health Incorporated Common Stock	C	B	B	$25.09
MDGLMadrigal Pharmaceuticals, Inc. Common Stock	D	A	C	$512.16
CYTKCytokinetics Inc.	F	D	B	$77.46
AXSMAxsome Therapeutics, Inc	D	B	C	$205.48
SMMTSummit Therapeutics Inc. Common Stock	F	—	D	$13.36
IONSIonis Pharmaceuticals, Inc. Common Stock	D	D	C	$63.57
ABVXAbivax SA American Depositary Shares	—	—	C	$117.93
RDYDr. Reddy's Laboratories Limited American Depositary Shares	D	D	C	$12.34
PRAXPraxis Precision Medicines, Inc. Common Stock	F	—	B	$368.02
NUVLNuvalent, Inc. Class A Common Stock	—	—	B	$123.96
PTGXProtagonist Therapeutics, Inc	F	B	A	$150.59
SYRESpyre Therapeutics, Inc. Common Stock	—	—	A	$107.36
CRNXCrinetics Pharmaceuticals, Inc.	F	A	A	$84.86
TGTXTG Therapeutics, Inc.	D	B	A	$55.42
ALKSAlkermes Inc. plc	D	C	B	$49.21
RYTMRhythm Pharmaceuticals, Inc. Common Stock	F	B	C	$113.35
ORKAOruka Therapeutics, Inc. Common Stock	F	—	A	$101.82
BLTEBelite Bio, Inc American Depositary Shares	—	—	B	$161.68
COGTCogent Biosciences, Inc. Common Stock	F	—	B	$36.80

About Kiora Pharmaceuticals, Inc. Common Stock

Kiora Pharmaceuticals is a clinical-stage biotechnology company developing therapies for rare retinal diseases. Its lead program, KIO-301, is a molecular photoswitch designed to restore vision in inherited retinal degenerative diseases including retinitis pigmentosa, choroideremia, and Stargardt disease. The company is also advancing KIO-104, a non-steroidal immunomodulator for posterior non-infectious uveitis.